Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies.

ABSTRACT: Since the approval of the first immune checkpoint inhibitor (ICI) 9 years ago, ICI-therapy have revolutionized cancer treatment. Lately, antibodies blocking the interaction of programmed cell death protein (PD-1) and ligand (PD-L1) are gaining momentum as a cancer treatment, with multiple agents and cancer types being recently approved for treatment by the US Food and Drug Administration (FDA). Unfortunately, immunotherapy often leads to a wide range of immune related adverse events (IRAEs), including several severe cardiac effects and most notably myocarditis. While increased attention has been drawn to these side effects, including publication of multiple clinical observational data, the underlying mechanisms are unknown. In the event of IRAEs, the most widely utilized clinical solution

SUBMITTER: Xu S 

PROVIDER: S-EPMC7887301 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature